Process Economics Program Report 238
Published: Dec-2001
The manufacture of chemical entities by Custom Manufacturing
Organizations (CMOs) is a $12 billion industry with a projected annual growth
rate (AGR) of 8-10%. Growth in this segment of the Fine Chemicals Industry is
being fueled by the pharmaceutical industry, both in the production of New Chemical
Entities (NCEs) as well as the manufacture of generic drugs.
The decision to outsource the manufacture of a chemical
entity versus building a dedicated facility for inhouse production requires
an understanding of the differences between a singleproduct plant where,” The
facility is designed for the process.” and a multiproduct plant where,”
The process is designed to fit the equipment in the facility.”
In this report PEP evaluates the production of a chiral
pharmaceutical intermediate, Lphenylalanine methylester hydrochloride, and the
generic pharmaceutical, fluoxetine, in a dedicated plant versus outsourcing
their production.
This report will be of interest to individuals responsible
for outsourcing the manufacture of New Chemical Entities (NCEs) in the chemical
and pharmaceutical industries as well as those organizations providing outsourcing
services.
For more information contact:
| 
